Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (966)	12/31/1997 11:47:00 AM
From: EZLibra	Read Replies (2) \| Respond to of 3702

Maurice, you can see that others are aware of this guy. Fifty cents is the same as $1.99 to a concentrated account on margin so we'll see how it plays out. On the competition you have missed some posts so I'll try to consolidate some answers, there's a lot of detritus to wade through on this thread. Tumors develop drug resistance but radiation always works even though there is a limit as to how much can be used. If you, the low grade NHL patient who has developed drug resistance (become refractory) have a choice between Rituxan with a 6-9% complete remission rate or Bexxar/Oncolym with a 50% complete remission rate which treatment would you choose? The fact that Idec is trying to develop Y2B8 (murine/radiation) shows the path of future treatment. Techniclone has tried the single dose on Intermediate and High Grade NHL and has determined that repeated, high dose injections are most effective. Y2B8 is blocked from a higher linkage of 40 mci by a Coulter patent and Bexxar is limited to a single dose because of high hama. In addition both Y2B8 and Bexxar bind to the CD20 antigen which is not as prevalent on the higher grade lymphomas as the HLA marker utilized by Oncolym. Antiangeogenesis requires a vascular system. Lymphomas and Leukemias are blood borne cancers so even if there is considerable debulking the cancer is still there. So you see, Maurice, the NHL market for mabs has a much longer duration that five years. You're on the right track though. Before too long we will see a trial in which solid tumors are debulked by VTA's and then the floating cancer cells are killed by TNT.